• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Summer 2023 increase in COVID-associated hospitalizations

Summer 2023 increase in COVID-associated hospitalizations

by Truveta Research | Aug 31, 2023 | Research, Research Insights

Compared to July, Truveta Data shows a 70.1% increase in the rate of COVID-19 positive tests and a 74.1% increase in the percentage of hospitalizations associated with COVID. Compared to 7 days prior, we see an 11.2% increase in the rate of COVID positive tests and an...
Moving from maternal health research to action

Moving from maternal health research to action

by Truveta Research | Aug 23, 2023 | Research, Research Insights

The United States has some of the highest rates of adverse maternal health outcomes compared to other high-income countries (Creanga et al., 2015; Gunja et al., 2022; Taylor et al., 2022). These outcomes have only increased in the last decade (Hoyert, 2023; U.S....
New research uses Truveta Data to study treatment for hospitalized pregnant patients with COVID-19

New research uses Truveta Data to study treatment for hospitalized pregnant patients with COVID-19

by Truveta staff | Jul 28, 2023 | Research

Scientists from the Institute for Systems Biology (ISB) have published new research in the JMIR Public Health and Surveillance journal. The work explores the National Institute of Health (NIH) recommendation for prophylactic anticoagulant use for pregnant patients...
Real-time monitoring of prescription trends and demographics of two SGLT2i drugs

Real-time monitoring of prescription trends and demographics of two SGLT2i drugs

by Truveta Research | Jul 10, 2023 | Research, Research Insights

We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends

Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends

by Truveta Research | Jun 6, 2023 | Research, Research Insights

Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
Truveta collaboration with Harvard University researchers published in JAMA Network Open

Truveta collaboration with Harvard University researchers published in JAMA Network Open

by Truveta Research | May 11, 2023 | News, Research

Today Truveta announced a new research letter published in JAMA Network Open using de-identified patient data from Truveta Studio. Published in collaboration with Anupam B. Jena, MD, PhD and Christopher M Worsham, MD, MPH from Harvard University, the new research...
« Older Entries
Next Entries »

Share this


Recent posts

  • Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data
  • Johns Hopkins builds research community to explore new frontiers in health using Truveta Data
  • Impact of the CVS GLP-1 formulary change: Trends in switching

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.